AN2 Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . AN2 Therapeutics
ANTX Stock  USD 1.13  0.01  0.88%   
AN2 Therapeutics financial statements provide useful quarterly and yearly information to potential AN2 Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on AN2 Therapeutics financial statements helps investors assess AN2 Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting AN2 Therapeutics' valuation are summarized below:
Market Capitalization
33.2 M
Earnings Share
(1.99)
We have found ninety-nine available fundamental measures for AN2 Therapeutics, which can be analyzed and compared to other ratios and to its peers in the sector. All investors should make sure to validate all of AN2 Therapeutics latest market performance against the performance between 2010 and 2025 to make sure the company can sustain itself this quarter and beyond. Market Cap is likely to drop to about 245.5 M in 2025. Enterprise Value is likely to drop to about 235.3 M in 2025
Check AN2 Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AN2 Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 84.1 M, Interest Expense of 620.7 K or Selling General Administrative of 17.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.24. AN2 financial statements analysis is a perfect complement when working with AN2 Therapeutics Valuation or Volatility modules.
  
Check out the analysis of AN2 Therapeutics Correlation against competitors.
For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide.

AN2 Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets167.5 M159.6 M43.4 M
Slightly volatile
Short and Long Term Debt Total45.3 K47.7 K474.1 K
Slightly volatile
Other Current Liabilities13.7 M13.1 M3 M
Slightly volatile
Total Current Liabilities17 M16.1 M3.8 M
Slightly volatile
Accounts Payable3.2 M3.1 M800.7 K
Slightly volatile
Cash14.2 M18 M9.2 M
Slightly volatile
Cash And Short Term Investments129.6 M123.4 M35.9 M
Slightly volatile
Common Stock Shares Outstanding21.8 M27.1 M19.8 M
Slightly volatile
Liabilities And Stockholders Equity167.5 M159.6 M43.4 M
Slightly volatile
Other Current Assets3.9 M3.7 M1 M
Slightly volatile
Total Liabilities15.3 M16.1 M12.4 M
Slightly volatile
Total Current Assets133.4 M127.1 M36.9 M
Slightly volatile
Other Liabilities14.8 K11.7 K20.6 K
Slightly volatile
Net Working Capital68 M110.9 M28.4 M
Slightly volatile
Non Currrent Assets Other915.7 K938.7 K1.5 M
Slightly volatile
Other Assets0.860.91.3 M
Slightly volatile
Deferred Long Term Liabilities1.4 M1.6 M1.7 M
Slightly volatile
Property Plant And Equipment Net42.4 K47.7 K52 K
Slightly volatile
Non Current Liabilities Other1.6 K1.8 K2 K
Slightly volatile
Short Term Debt84.8 K95.4 K104 K
Slightly volatile
Net Receivables1.1 M1.3 M1.4 M
Slightly volatile

AN2 Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative17.8 M17 M5.3 M
Slightly volatile
Selling And Marketing Expenses17.8 M17 M6 M
Slightly volatile
Other Operating Expenses84.1 M80.1 M22.3 M
Slightly volatile
Research Development66.3 M63.1 M17.8 M
Slightly volatile
Total Operating Expenses84.1 M80.1 M22.3 M
Slightly volatile
Net Interest Income1.6 M1.6 M374.3 K
Slightly volatile
Interest Income1.6 M1.6 M374.3 K
Slightly volatile
Cost Of Revenue61.6 K69.3 K75.6 K
Slightly volatile

AN2 Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Cashflows From Financing Activities397.6 K418.5 K35.7 M
Slightly volatile
Total Cash From Financing Activities54.1 M97.7 M29.4 M
Slightly volatile
End Period Cash Flow14.2 M18 M9.2 M
Slightly volatile
Change To Netincome6.2 M3.4 M13.4 M
Slightly volatile
Stock Based Compensation10.2 M9.7 M2.1 M
Slightly volatile
Begin Period Cash Flow32.9 M31.3 M10.6 M
Slightly volatile
Issuance Of Capital Stock65.6 M97.6 M27.5 M
Slightly volatile
Dividends Paid1.5 M1.6 M1.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Payables Turnover0.0290.03270.0356
Slightly volatile
Cash Per Share2.14.091.376
Slightly volatile
Days Payables Outstanding8 K9.1 K9.9 K
Slightly volatile
Income Quality0.550.740.5429
Slightly volatile
Current Ratio17.179.0526.6819
Slightly volatile
Graham Number17.0616.255.7631
Slightly volatile
Debt To Equity6.0E-46.0E-40.0948
Slightly volatile
Interest Debt Per Share0.03740.03360.036
Slightly volatile
Debt To Assets6.0E-46.0E-40.08
Slightly volatile
Days Of Payables Outstanding8 K9.1 K9.9 K
Slightly volatile
Ebt Per Ebit1.291.071.1255
Pretty Stable
Long Term Debt To Capitalization0.10.120.1287
Slightly volatile
Total Debt To Capitalization6.0E-46.0E-40.0823
Slightly volatile
Debt Equity Ratio6.0E-46.0E-40.0948
Slightly volatile
Quick Ratio17.179.0526.6819
Slightly volatile
Net Income Per E B T0.80.910.9831
Slightly volatile
Cash Ratio1.221.2822.8644
Slightly volatile
Debt Ratio6.0E-46.0E-40.08
Slightly volatile

AN2 Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap245.5 M435.2 M300.8 M
Pretty Stable
Enterprise Value235.3 M421.1 M292.5 M
Pretty Stable

AN2 Fundamental Market Drivers

Cash And Short Term Investments107.3 M

AN2 Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About AN2 Therapeutics Financial Statements

AN2 Therapeutics investors use historical fundamental indicators, such as AN2 Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in AN2 Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue69.3 K61.6 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CRMSalesforce
CCitigroup
GMGeneral Motors

Additional Tools for AN2 Stock Analysis

When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY